Animal Models Market

• The Animal Models Market is growing due to increased demand for preclinical research and drug development

• Rising focus on disease modeling, genetic research, and translational studies is driving the development of specialized animal models.

• Advancements in genetically engineered and transgenic models are enhancing the accuracy of human disease simulations and therapeutic testing.

• Increasing regulatory emphasis on ethics, reproducibility, and humane research practices is promoting the use of standardized and well-characterized animal models.

• Emerging alternatives such as 3D tissue models and organ-on-a-chip systems are complementing traditional animal models and supporting refinement in preclinical studies.

• Collaborations between research institutes, pharmaceutical companies, and animal model suppliers are fostering innovation and access to diverse model systems.

• Growth in biomarker discovery, immunotherapy, and rare disease research is boosting the adoption of specialized animal models for targeted studies.

• In August 2023, Biocytogen restructured its operations by forming two business divisions to distinguish its antibody-drug research and development from its preclinical models and services (BioMice). This strategic move aims to enhance specialization and drive innovation across its core business areas.

• In April 2023, Merck strengthened its immunology program through the acquisition of Prometheus Biosciences, Inc., expanding its portfolio in autoimmune disease therapies and reinforcing its position in the biopharmaceutical research sector.

In this report, the Animal Models Market has been segmented by Animal Type, Application, End-Use, and Geography. This segmentation presents how species selection, disease focus, user-type adoption and regional research ecosystems collectively shape growth, investment and competitive strategy in the animal model domain.

Animal Models Market, Segmentation by Animal Type

The animal type segmentation reflects how different species (such as mice, rats, guinea pigs, rabbits, hamsters and others) are used as models in preclinical research, driven by cost, genetic manipulability, regulatory acceptance and translational relevance. **Mice and rats dominate** due to broad use in drug discovery, toxicology and genetic studies, whereas species like guinea pigs, rabbits or hamsters fill niche or specialised roles.

Mice

The mice segment holds a dominant share in the animal models market, due to their high genetic homology with humans, ease of breeding, and widespread availability of transgenic strains. According to one source, the mice segment accounted for approximately 65 % of the market by species in a recent study. :contentReference[oaicite:0]{index=0} This makes them central to oncology, immunology and infectious disease research.

Rat

The rat segment continues to be significant, especially in physiology, neuroscience and toxicology models where larger body size and established protocols provide advantages. Although genetic modification is somewhat more complex than in mice, rats remain a key model organism in the research community and a critical growth segment as translational requirements increase.

Guinea Pigs

The guinea pigs segment is increasingly notable for niche applications—such as immunology and auditory research—where their physiology offers distinct advantages. Some reports indicate this segment is projected to grow at a higher CAGR compared to certain other species. :contentReference[oaicite:1]{index=1}

Rabbits

The rabbits segment is used extensively in ophthalmology, dermatology, vaccine development and certain immunological studies. Their moderate size, cost and established regulatory acceptance make them a common choice for intermediate-scale in vivo testing and model development.

Hamsters

The hamsters segment is used in specialised infectious disease and metabolic disorder research due to certain unique physiological responses (e.g., viral susceptibility). As preclinical research diversifies, hamsters are gaining interest for models of newer diseases and tailored drug development workflows.

Others

The others segment covers species such as guinea pigs (if not separately counted), ferrets, non-rodents or emerging exotic models that fill very specific research niches (e.g., larger mammals, primates, or custom engineered species). This segment is growing as demand for more human-relevant models increases and regulatory scrutiny intensifies.

Animal Models Market, Segmentation by Application

The application segmentation shows how animal models are deployed across key disease or research domains—such as cancer, immunological disease, infectious disease and other applications. The choice of application influences model complexity, cost, required infrastructure and regulatory burden. Growth in drug discovery, biologics and gene therapies is accelerating demand across all these applications.

Cancer

The cancer segment represents the largest application share in the animal models market, supported by high R&D spending, the prevalence of oncology programmes, and growing requirement for sophisticated preclinical models (e.g., patient-derived xenografts). One market analysis shows the cancer segment held approximately 44 % of the application share in 2023. :contentReference[oaicite:2]{index=2}

Immunological Disease

The immunological disease segment is expanding strongly due to the rise of biologics, immunotherapies, autoimmune disease research and combination treatments. Animal models tailored for immune response, inflammation and novel targets are seeing higher demand as the pharmaceutical industry moves into more complex therapeutic areas.

Infectious Disease

The infectious disease segment has regained prominence, driven by global public-health priorities, vaccine development, outbreak response and zoonotic disease research. Models for pathogens, viruses and host-pathogen interactions are being rapidly refined and deployed, boosting this segment’s growth trajectory.

Others

The others segment covers applications such as neurology, metabolic disorders, cardiovascular disease, toxicity and safety-pharmacology where animal models are used for preclinical validation, safety assessment and translational research. While individually smaller, these applications are aggregating to significant demand.

Animal Models Market, Segmentation by End-Use

The end-use segmentation categorises how organisations adopt animal models—from pharmaceutical & biotechnology companies to academic research institutes and contract research organisations (CROs). Differences in scale, funding, regulatory compliance and service models lead to differing growth rates and strategic needs across these segments.

Pharmaceutical & Biotechnology Companies

The pharmaceutical & biotechnology companies segment dominates the market, leveraging in-house vivarium facilities, internal research pipelines and partnerships for novel therapeutic development. According to market reports, this segment was the major revenue contributor in 2024. :contentReference[oaicite:3]{index=3}

Academic Research Institute

The academic research institute segment includes universities, public-sector labs and research centres engaged in basic science, translational research and early-phase drug discovery. Although smaller in commercial revenue, this segment drives innovation, model development and early-stage collaborations and is a strategic partner for CROs and industry.

Contract Research Organization (CRO)

The CRO segment is growing fastest among end-users as pharmaceutical and biotech firms increasingly outsource preclinical animal-model work to specialised providers for cost-efficiency, scalability and regulatory compliance support. Market data suggest this segment is expected to register the highest CAGR among the user categories. :contentReference[oaicite:4]{index=4}

Animal Models Market, Segmentation by Geography

The geography segmentation examines regional dynamics of the animal models market across key geographies—North America, Europe, Asia Pacific, Middle East & Africa and Latin America. Factors such as regional research infrastructure, funding levels, regulatory frameworks and model-service ecosystems affect market penetration, growth and strategic focus.

North America

In North America, the animal models market is firmly supported by a mature biopharma ecosystem, high preclinical R&D spend, strong regulatory requirements for animal-based testing and extensive service provider infrastructure. Market data indicate North America accounted for approximately 48.95 % of the global market share in 2022. :contentReference[oaicite:5]{index=5} Growth continues as innovation and outsourcing trends advance.

Europe

Europe benefits from a well-established research infrastructure, stringent ethical/regulatory frameworks for animal research, and strong academic-industry collaborations. While cost pressures and alternative model technologies (e.g., in-vitro) influence some headwinds, Europe remains a key strategic region for animal-model providers and preclinical services.

Asia Pacific

Asia Pacific is emerging as the fastest-growing region in the animal models market, driven by rising investment in life sciences (especially China and India), increasing outsourcing of preclinical studies, growing domestic biotech/ pharma activity and expanding animal-model service infrastructure. One source projects the region to capture significant incremental opportunity through 2034. :contentReference[oaicite:6]{index=6}

Middle East & Africa

The Middle East & Africa region remains nascent in the animal models market but is gradually developing research infrastructure, regulatory frameworks and collaborative partnerships. While current volumes are lower compared to developed regions, long-term growth potential exists through government initiatives, regional hubs and contract service growth.

Latin America

Latin America presents moderate growth opportunities in the animal models market, supported by a growing number of pharmaceutical/biotech enterprises, increasing clinical research outsourcing and regional cost arbitrage advantages. However, slower adoption, regulatory variability and infrastructure constraints remain challenges.

This report provides an in depth analysis of various factors that impact the dynamics of Global Animal Model Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers:

• Increasing pet ownership
• Rising prevalence of zoonotic diseases
• Growing demand for protein-rich diets

• Government initiatives promoting animal health -Government initiatives promoting animal health play a pivotal role in shaping the global animal model market. These initiatives encompass a range of activities aimed at enhancing the well-being of animals through research, disease prevention, and treatment advancements. In many countries, governments allocate substantial funding towards veterinary research and development, which directly influences the demand for animal models used in scientific studies. Such initiatives often prioritize the development of new therapies, vaccines, and diagnostic tools to combat prevalent animal diseases and ensure the sustainability of livestock production.

  Government regulations and policies regarding animal testing standards also impact the animal model market. Stringent guidelines ensure ethical practices in research involving animals, fostering the development of more humane and effective experimental methods. These regulations not only safeguard animal welfare but also stimulate innovation in the development of alternative testing methods, such as in vitro and computational models, which could potentially reduce the dependence on animal models in research.

  Governmental support extends to collaborations between research institutions, pharmaceutical companies, and academic organizations, aiming to accelerate the discovery of novel treatments and vaccines. Such partnerships often leverage animal models to study complex diseases and validate drug efficacy before clinical trials, thereby reducing risks and costs associated with drug development.

  In conclusion, government initiatives promoting animal health drive significant growth and innovation within the global animal model market. By fostering research, enhancing regulatory frameworks, and encouraging collaboration, governments play a crucial role in advancing scientific discoveries that benefit both animal and human health worldwide. These efforts ensure that the use of animal models remains integral to biomedical research while upholding ethical standards and promoting advancements in veterinary care and animal welfare.

Restraints:

• High cost of animal healthcare products
• Lack of skilled veterinarians in certain regions
• Resistance to antimicrobial drugs

• Reimbursement policies for animal treatments -Reimbursement policies play a crucial role in shaping the global animal model market, which is integral to biomedical research and pharmaceutical development. These policies dictate how expenses related to animal treatments and research are covered, influencing the affordability and accessibility of such experiments. In many regions, reimbursement policies vary significantly, impacting the adoption and utilization of animal models in research.

  Countries with robust reimbursement frameworks often see higher levels of investment in animal model research, as researchers and pharmaceutical companies are more assured of recovering costs associated with experimental treatments. This financial predictability encourages innovation and experimentation, driving advancements in areas like disease modeling, drug efficacy testing, and toxicity studies.

  Regions with less comprehensive reimbursement policies may experience slower growth in their animal model markets. Uncertain financial outcomes can deter stakeholders from investing in extensive research involving animals, thereby potentially limiting scientific progress and therapeutic breakthroughs.

  Evolving ethical considerations around animal welfare also influence reimbursement policies, with stricter regulations sometimes leading to higher operational costs and increased scrutiny on the necessity and ethical handling of animal experiments.

  In conclusion, while reimbursement policies may seem administrative, they profoundly impact the dynamics of the global animal model market. By providing financial incentives and regulatory frameworks, these policies shape the landscape of biomedical research, impacting innovation, ethical practices, and ultimately the development of new treatments and therapies. Thus, understanding and adapting to these policies is essential for stakeholders in both the research and pharmaceutical sectors to navigate and contribute effectively to this critical field.

Opportunities:

• Expansion in emerging markets
• Development of personalized veterinary medicine
• Focus on preventive healthcare for animals

• Increasing investments in R&D for innovative products -The global animal model market is experiencing significant growth, driven largely by increasing investments in research and development aimed at developing innovative products. Animal models play a crucial role in biomedical research, providing essential insights into human diseases, drug efficacy, and safety. As pharmaceutical and biotechnology companies continue to expand their pipelines with novel therapeutics, the demand for reliable and predictive animal models has surged.

  Investments in R&D are not only fueling advancements in disease modeling and drug discovery but also enhancing the overall quality and diversity of animal models available. This includes genetically engineered models that closely mimic human conditions, thereby improving the translatability of preclinical research to clinical outcomes. The pharmaceutical industry, in particular, relies heavily on animal models to assess drug toxicity, pharmacokinetics, and efficacy before advancing to human trials, thereby reducing risks and costs associated with drug development.

  Academic and government research institutions are also contributing to the expansion of the animal model market by conducting fundamental research across a wide range of disciplines, from neuroscience to oncology. This collaborative effort between public and private sectors is fostering innovation and driving the adoption of sophisticated animal models that better reflect human biology.

  Advancements in technologies such as CRISPR/Cas9 gene editing and 3D bioprinting are expected to further revolutionize the field by enabling precise modifications and the creation of more complex model systems. These innovations promise to accelerate research timelines and enhance the predictive power of preclinical studies, ultimately leading to the development of safer and more effective therapies.

  In conclusion, the global animal model market is poised for continued growth, supported by robust investments in R&D and technological advancements. As stakeholders across various sectors strive to address unmet medical needs and improve healthcare outcomes, the role of animal models as indispensable tools in biomedical research is set to expand, driving innovation and shaping the future of medicine.

Animal Models Market is defined by competition among biotechnology firms, research institutions, and laboratory suppliers. Companies adopt strategies such as mergers, partnerships, and collaboration to enhance model diversity, genetic relevance, and reproducibility. With nearly 60% of share concentrated among leading players, continuous innovation in genetically modified models, disease-specific strains, and preclinical testing drives steady growth across pharmaceutical, academic, and clinical research applications.

Market Structure and Concentration
The industry demonstrates moderate concentration, with about 55% of revenues controlled by multinational animal model providers. Regional suppliers contribute to expansion through customized models and cost-effective solutions. This combination of consolidated leadership and fragmented innovation shapes competitive strategies, ensuring consistent growth in animal model utilization for research and development.

Brand and Channel Strategies
Leading firms strengthen their brands through partnerships with research organizations, collaborations with distributors, and direct contracts with pharmaceutical companies. Nearly 60% of adoption occurs via research institutions and laboratories, while contract research organizations and online platforms support channel expansion. Effective strategies emphasize model reliability, ethical compliance, and scientific relevance, reinforcing sustainable growth in the market.

Innovation Drivers and Technological Advancements
Ongoing innovation focuses on genetically engineered models, humanized systems, and disease-specific strains. Around 45% of R&D investments target technological advancements that improve translational research, reproducibility, and study outcomes. Strategic collaboration between manufacturers and research institutions drives strategies, enabling measurable growth in preclinical and biomedical research applications.

Regional Momentum and Expansion
North America accounts for nearly 40% of demand, driven by pharmaceutical research and clinical studies. Europe demonstrates steady growth with academic and biotech adoption, while Asia-Pacific shows rapid expansion surpassing 25% due to increasing R&D investments and government-backed research programs. Regional strategies enhance market penetration and competitive positioning.

Future Outlook
The market is projected to sustain robust growth as demand for precise, ethical, and diverse animal models rises. Stronger partnerships and mergers will reshape competitive landscapes, while continuous innovation ensures improved model relevance, reproducibility, and research efficiency. The future outlook highlights broad expansion supported by biomedical research growth, technological advancements, and pharmaceutical development trends.

Key players in Animal Model Market include.

• Charles River Laboratories International, Inc.
• The Jackson Laboratory
• Taconic Biosciences, Inc.
• GenOway S.A.
• Eurofins Scientific SE
• Crown Bioscience, Inc.
• Envigo (Inotiv, Inc.)
• Labcorp Drug Development
• Horizon Discovery Group
• Transposagen Biopharmaceuticals, Inc.
• Biocytogen Pharmaceuticals Co., Ltd.
• Cyagen Biosciences, Inc.
• Janvier Labs
• Ozgene Pty Ltd.
• GemPharmatech

In this report, the profile of each market player provides following information:

• Market Share Analysis
• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis